A retrospective study of proteinuria in dogs receiving toceranib phosphate.
| Autor: | Piscoya SL; Cornell University College of Veterinary Medicine - Clinical Sciences, VMC Box 31, Ithaca, New York 14853-6401, USA., Hume KR; Cornell University College of Veterinary Medicine - Clinical Sciences, VMC Box 31, Ithaca, New York 14853-6401, USA., Balkman CE; Cornell University College of Veterinary Medicine - Clinical Sciences, VMC Box 31, Ithaca, New York 14853-6401, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Canadian veterinary journal = La revue veterinaire canadienne [Can Vet J] 2018 Jun; Vol. 59 (6), pp. 611-616. |
| Abstrakt: | The incidence of proteinuria in humans receiving tyrosine kinase inhibitors has been well-documented. Reports of proteinuria with this class of drugs are limited in veterinary medicine. This retrospective study describes the incidence, severity, and progression of proteinuria in 55 dogs treated with toceranib phosphate, with or without concurrent glucocorticoid or NSAID (non-steroidal anti-inflammatory drug). Six dogs were proteinuric at baseline. Twelve of the 49 dogs that were not proteinuric at baseline developed proteinuria while receiving toceranib phosphate. Median urine protein:creatinine (UPC) ratio when proteinuria developed was 0.75 (range: 0.6 to 4.9). There was no association with intermittent glucocorticoid or NSAID use and development of proteinuria ( P = 0.5 and P = 0.7, respectively). Overall duration of toceranib phosphate treatment ranged from 70 to 802 days in proteinuric dogs and 28 to 1285 days in non-proteinuric dogs. Our results indicate a subset of dogs receiving toceranib phosphate may develop proteinuria; careful monitoring with serial UPCs is recommended. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|